ERD-3111

• UNSPSC Description:

  ERD-3111 (Compound 44) is an orally active PROTAC ERα degrader (DC50: 0.5 nM). ERD-3111 inhibits tumor growth in the parental MCF-7 xenograft model with wild-type ER and two clinically relevant ESR1 mutated mice model. ERD-3111 can be used in the research of ER+ breast cancer[1].

• Target Antigen:

  Estrogen Receptor/ERR; PROTACs

• Type:

  Reference compound

• Related Pathways:

  PROTAC;Vitamin D Related/Nuclear Receptor

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/erd-3111.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  FC(CN1[C@@H](CC2=C([C@H]1C3=C(C=C(C=C3F)N4CCC5(CC4)CCN(C(CN6CC(C=C(C7=C8)C(N(C7=O)C9CCC(NC9=O)=O)=O)=C8C6)=O)CC5)F)C=CC%10=C2C=NN%10)C)F

• Molecular Weight:

  854.89

• References & Citations:

  [1]Chen Z, et al. Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity. J Med Chem. 2023 Aug 30.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  2832865-25-3